KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Non-cash Items (2016 - 2025)

Sarepta Therapeutics has reported Non-cash Items over the past 15 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Non-cash Items at $5.8 million for Q4 2025, down 7.71% from a year ago — trailing twelve months through Dec 2025 was $5.8 million (down 7.71% YoY), and the annual figure for FY2025 was $5.8 million, down 7.71%.
  • Non-cash Items for Q4 2025 was $5.8 million at Sarepta Therapeutics, down from $6.3 million in the prior quarter.
  • Over the last five years, Non-cash Items for SRPT hit a ceiling of $288.1 million in Q4 2023 and a floor of $4.7 million in Q4 2022.
  • Median Non-cash Items over the past 5 years was $6.3 million (2024), compared with a mean of $110.7 million.
  • Biggest five-year swings in Non-cash Items: soared 12198.98% in 2021 and later plummeted 98.11% in 2022.
  • Sarepta Therapeutics' Non-cash Items stood at $248.5 million in 2021, then plummeted by 98.11% to $4.7 million in 2022, then surged by 6039.89% to $288.1 million in 2023, then tumbled by 97.82% to $6.3 million in 2024, then fell by 7.71% to $5.8 million in 2025.
  • The last three reported values for Non-cash Items were $5.8 million (Q4 2025), $6.3 million (Q4 2024), and $288.1 million (Q4 2023) per Business Quant data.